GRCL Live signals | Maximize Profits with Getagraph.com

BUY 99128 min ago

@ CNY10.28

Issued: 14 Feb 2024 @ 15:48

Return: -0.29%

Previous signal: Feb 14 - 13:13

Previous signal: Sell

Return: -0.48 %

Live Chart Being Loaded With Signals

Commentary (21 Feb 2024 @ 16:00):

Gracell Biotechnologies Inc., a clinical-stage biopharmaceutical company, primarily discovers and develops cell therapies for the treatment of cancer in the People's Republic of China...

Stats
Today's Volume	6.37M
Average Volume	1.46M
Market Cap	989.87M
EPS	CNY0 ( 2024-03-11 )
Next earnings date	( CNY0 ) 2024-05-13
Last Dividend	CNY0 ( N/A )
Next Dividend	CNY0 ( N/A )
P/E	-10.57
ATR14	CNY0.215 (2.10%)

Volume Correlation

Long: 0.31 (neutral)

Short: 0.24 (neutral)

Signal:(68.183) Neutral

Gracell Biotechnologies Correlation

10 Most Positive Correlations
ENPH	0.931
BLU	0.927
ATAI	0.922
NNOX	0.916
PTPI	0.915
RDHL	0.915
RXT	0.915
IMCC	0.91
PAVM	0.908
VORB	0.905

10 Most Negative Correlations
ITMR	-0.929
OPNT	-0.929
AVEO	-0.925
VLYPP	-0.923
DVCR	-0.923
CIH	-0.918
BKCH	-0.916
FRGI	-0.915
EWEB	-0.907
MLCO	-0.901

Did You Know?

Correlation is a statistical measure that describes the relationship between two variables. It ranges from -1 to 1, where -1 indicates a perfect negative correlation (as one variable increases, the other decreases), 1 indicates a perfect positive correlation (as one variable increases, the other increases), and 0 indicates no correlation (there is no relationship between the variables).

Correlation can be used to analyze the relationship between any two variables, not just stocks. It's commonly used in fields such as finance, economics, psychology, and more.

Gracell Biotechnologies Correlation - Currency/Commodity

0.84
( strong )

0.83
( strong )

-0.53
( weak negative )

0.54
( weak )

-0.12
( neutral )

0.08
( neutral )

Gracell Biotechnologies Financials

Annual	2022
Revenue:	CNY0
Gross Profit:	CNY0 (0.00 %)
EPS:	CNY-5.65

Q3	2023
Revenue:	CNY0
Gross Profit:	CNY0 (0.00 %)
EPS:	CNY-0.810

Q2	2023
Revenue:	CNY0
Gross Profit:	CNY0 (0.00 %)
EPS:	CNY-2.15

Q1	2023
Revenue:	CNY0
Gross Profit:	CNY0 (0.00 %)
EPS:	CNY-2.24

Financial Reports:

No articles found.

Gracell Biotechnologies

Gracell Biotechnologies Inc., a clinical-stage biopharmaceutical company, primarily discovers and develops cell therapies for the treatment of cancer in the People's Republic of China. Its lead product candidates include GC012F, a FasTCAR-enabled dual BCMA- and CD19-directed autologous CAR-T product candidate that is in Phase I trial for the treatment of multiple myeloma; GC019F, a FasTCAR-enabled CD19-directed autologous CAR-T product candidate, which is in Phase I clinical trial for the treatment of adult B cell acute lymphoblastic leukemia (B-ALL), as well as in preclinical stage for the treatment of relapsed or refractory (r/r) B cell non-Hodgkin's lymphoma (B-NHL); and GC027, a TruUCAR-enabled CD7-directed allogeneic CAR-T product candidate, which is in Phase I clinical trial for the treatment of adult T cell acute lymphoblastic leukemia. The company's product candidates also comprise GC007g, a donor-derived CD19-directed allogeneic CAR-T cell therapy that is in Phase 1/2 registrational trial clinical trial for the treatment of r/r B-ALL; and GC502, a TruUCAR-enabled dual CD19- and CD7 -directed, off-the-shelf allogeneic CAR-T product candidate, which is in Phase I trial for the treatment of B-cell malignancies. In addition, it has a portfolio of earlier stage product candidates targeting various cancer indications, such as ovarian cancer, breast cancer, peripheral T cell lymphoma, a subtype of NHL, and T cell lymphoblastic leukemia. The company was founded in 2017 and is headquartered in Suzhou, China.